var data={"title":"Amantadine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amantadine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5604?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">see &quot;Amantadine: Drug information&quot;</a> and <a href=\"topic.htm?path=amantadine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amantadine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50907068\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Influenza Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Centers for Disease Control and Prevention (CDC) is reporting a significant increase in influenza activity over recent weeks, with influenza A(H3N2) viruses predominating. Past A(H3N2) virus-predominant influenza seasons have been associated with more hospitalizations and deaths in persons 65 years of age and older, as well as in young children, compared to other age groups. Influenza vaccine effectiveness has also been generally lower against A (H3N2) viruses than against influenza A (H1N1) pdm09 or influenza B viruses. Last influenza season, vaccine effectiveness against circulating A (H3N2) viruses was estimated to be 32% in the US and is expected to be similar this season if the same A (H3N2) viruses continue to predominate. Influenza activity was high in the Southern Hemisphere in 2017 and preliminary data from Australia suggest overall vaccine effectiveness of 33% but only 10% against A (H3N2) viruses, making the use of antiviral medications for treatment of influenza, in addition to preventive vaccination, even more important.</p>\n        <p style=\"text-indent:0em;\">The CDC has also issued a health advisory stating that all hospitalized patients, patients with severe, complicated, or progressive illness (including outpatients), and all high-risk patients (including pediatric patients younger than 2 years; adults 65 years and older; patients with certain chronic illnesses or neurologic or neurodevelopmental conditions; immunosuppressed patients; women who are pregnant or postpartum (within 2 weeks of delivery); patients younger than 19 years of age receiving long term aspirin therapy; American Indians/Alaska Natives; patients with BMI of 40 or more; and residents of nursing homes or other chronic-care facilities) with suspected or confirmed influenza should be treated as soon as possible with a neuraminidase inhibitor antiviral (eg, oseltamivir, peramivir, zanamivir). Adamantanes (eg, amantadine, rimantadine) are not currently recommended for treatment or prophylaxis of influenza A because of high levels of resistance. Antivirals for influenza work best when initiated within 48 hours of illness onset; however, clinical benefit has been observed even when treatment is initiated later in some patients.</p>\n        <p style=\"text-indent:0em;\">Further information is available at <a target=\"_blank\" href=\"https://emergency.cdc.gov/han/han00409.asp&amp;token=/XpciKoGXD/NBcI56myByIrj6XDzXmi2bFm6I7VYATsTAoPzpN4M+ut5dGKrD6OM&amp;TOPIC_ID=13387\" target=\"_blank\">https://emergency.cdc.gov/han/han00409.asp</a> and <a target=\"_blank\" href=\"https://www.cdc.gov/flu/weekly/summary.htm&amp;token=R4Uiw8/bmPVaqNHRDqpXLOtzxb+vTZhOOrHrvoZzklFBp7r1xCTELF4KBDcLrJouICpPDwRTIgOkmOCDxEXvOQ==&amp;TOPIC_ID=13387\" target=\"_blank\">https://www.cdc.gov/flu/weekly/summary.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50642731\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gocovri</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044970\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anti-Parkinson's Agent (Dopamine Agonist)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Adamantane</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044963\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">see &quot;Amantadine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD):</b> Limited data available: Oral: Children &ge;5 years and Adolescents: Initial: 50 mg/<b>day</b>; titrate up at 4-7 day intervals in 50 mg increments to effect; reported range: 50-150 mg/<b>day</b> in divided doses 1-3 times daily (morning, noon, and 4 PM); maximum daily dose (weight-dependent): &lt;30 kg: 100 mg/<b>day</b>; &ge;30 kg: 150 mg/<b>day</b> (Donfrancecso, 2007; King, 2001; Mohammadi, 2010); dosing based on two small open-label trials (n=24, n=20; age range: 5-14 years) which suggested improvements in symptoms and ADHD outcome scores; a comparison trial with methylphenidate (n=40) did not detect differences in efficacy between the treatment groups (Mohammadi, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Autism (hyperactivity, irritability):</b> Limited data available: Oral: Children &ge;5 years and Adolescents: Initial: 2.5 mg/kg/dose once daily for 1 week, then increase to 2.5 mg/kg/dose twice daily; maximum daily dose: 200 mg/<b>day</b>; dosing based on short-term (4-week) double-blind, placebo-controlled trial of 39 pediatric patients (treatment group, n=19) which showed improvement in clinician-rated behavioral and hyperactivity ratings (King, 2001a).  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Influenza A treatment/prophylaxis:</b> Oral: <b>Note:</b> Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A. Please refer to the current ACIP recommendations. The following is based on the manufacturer's labeling and ACIP recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Influenza A treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">1-9 years: 5 mg/kg/<b>day</b> in 2 divided doses (manufacturer's labeling: 4.4-8.8 mg/kg/<b>day</b>); maximum daily dose: 150 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;10 years and &lt;40 kg: 5 mg/kg/<b>day</b> in 2 divided doses (CDC, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;10 years and &ge;40 kg: 100 mg twice daily (CDC, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">\n      <b>Note:</b> Initiate within 24-48 hours after onset of symptoms; continue for 24-48 hours after symptom resolution (duration of therapy is generally 3-5 days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Influenza A prophylaxis:</i> Refer to &quot;Influenza A treatment&quot; dosing</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <b>Note:</b> Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed. For ages &lt;9 years receiving influenza vaccine for the first time, amantadine prophylaxis should continue for 6 weeks (4 weeks after the first dose and 2 weeks after the second dose).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Multiple-sclerosis associated lassitude (fatigue):</b> Limited data available (Pohl, 2007): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;10 years or weight &lt;40 kg:  2.5 mg/kg/dose twice daily; maximum daily dose: 150 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;10 years and weight &ge;40 kg: 100 mg twice daily, may titrate dose to clinical response; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Traumatic brain injury (TBI):</b> Limited data available: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;6 years and Adolescents &lt;16 years: 4-6 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose (age or weight dependent): If &lt;10 years or &lt;40 kg: 150 mg/<b>day</b>; if &ge;10 years or &ge;40 kg: 200 mg/<b>day</b> (Beers, 2005; McMahon, 2009). While total daily dose similar in trials, the reported dosing approaches and efficacy results are variable (eg, timing of therapy initiation, duration of study, outcome measures) (Williams, 2007). In an open-label, case-controlled trial of 27 pediatric patients with TBI within the last 24 months prior to enrollment (n=17 amantadine treatment, n=10 controls), patients received 5 mg/kg/<b>day</b> for entire study period of 12 weeks; results showed improvement in behavior (parental report) and a subset analysis suggested therapy more effective on cognition for those with more recent injury (Beers, 2005). In a double-blind, placebo-controlled crossover trial of seven pediatric patients (mean age: 12.7 years) with TBI within last 12 weeks prior to enrollment, therapy was initiated at 4 mg/kg/<b>day</b> up to 300 mg/<b>day</b> for 1 week, and increased to 6 mg/kg/<b>day</b> up to 400 mg/<b>day</b> for Weeks 2 and 3 of the study duration; improved consciousness observed during treatment period of study (McMahon, 2009; Vargus-Adams, 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents &ge;16 years: Initial: 100 mg twice daily for 14 days; on Week 3 increase to 150 mg twice daily; may further increase to 200 mg twice daily on Week 4 if needed; dosing based on a multicenter, double-blind, placebo-controlled trial of 184 patients (age range: 16-65 years; treatment group, n= 87) which showed 4 weeks of amantadine therapy initiated at 4-16 weeks postinjury increased the rate of functional recovery (Giacino, 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Drug-induced extrapyramidal symptoms:</b> Oral: 100 mg twice daily; may increase to 300 mg/day in divided doses, if needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Parkinson's disease:</b> Oral: Usual dose: 100 mg twice daily as monotherapy; may increase to 400 mg/day in divided doses, if needed, with close monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> Patients with a serious concomitant illness or those receiving high doses of other antiparkinson drugs should be started at 100 mg/day; may increase to 100 mg twice daily, if needed, after one to several weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Influenza A treatment/prophylaxis:</b> Oral: <b>Note:</b> Due to issues of resistance, amantadine is no longer recommended for the treatment or prophylaxis of influenza A. Please refer to the current ACIP recommendations. The following is based on the manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Influenza A treatment:</i> 200 mg once daily <b>or</b> 100 mg twice daily (may be preferred to reduce CNS effects)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <b>Note:</b> Initiate within 24-48 hours after onset of symptoms; continue for 24-48 hours after symptom resolution (duration of therapy is generally 3-5 days)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Influenza A prophylaxis:</i> 200 mg once daily <b>or</b> 100 mg twice daily (may be preferred to reduce CNS effects)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <b>Note:</b> Continue prophylaxis throughout the peak influenza activity in the community or throughout the entire influenza season in patients who cannot be vaccinated. Development of immunity following vaccination takes ~2 weeks; amantadine therapy should be considered for high-risk patients from the time of vaccination until immunity has developed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing interval in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30-50 mL/minute: Administer 200 mg on day 1, then 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 15-29 mL/minute: Administer 200 mg on day 1, then 100 mg on alternate days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;15 mL/minute: Administer 200 mg every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis: Negligible amount removed during hemodialysis:  Administer 200 mg every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peritoneal dialysis: No supplemental dose is needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous arteriovenous or venous-venous hemofiltration: No supplemental dose is needed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132650\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gocovri: 68.5 mg, 137 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (10 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132635\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51128489\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Osmolex ER tablets: FDA approved February 2018; anticipated availability is currently unknown. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15574778\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be taken without regard to food. For regimens with multiple daily dosing, timing of doses may vary based upon patient tolerance (eg, if insomnia develops,  administer evening dose several hours before bedtime) and use [for ADHD, administer morning and noon; if thrice daily dosing, last dose should be given around 4 PM (Mohammadi, 2010)].</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132671\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect capsules from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044972\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis and treatment of influenza A viral infection (FDA approved in ages &ge;1 year and adults); <b>Note:</b> Due to high resistance rates, amantadine is no longer recommended by the CDC for the treatment or prophylaxis of influenza A (CDC, 2011); symptomatic and adjunct treatment of parkinsonism; treatment of drug-induced extrapyramidal reactions (FDA approved in adults); has also been used for attention-deficit/hyperactivity disorder (ADHD), autism, fatigue associated with multiple sclerosis, and in post-traumatic brain injury for behavior and cognition</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132723\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amantadine may be confused with amiodarone, raNITIdine, riMANTAdine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Symmetrel may be confused with Synthroid</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132720\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Livedo reticularis (may be more common in women), orthostatic hypotension (may be more common in men), peripheral edema, presyncope, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams (may be more common in women), agitation, anxiety, apathy, ataxia (may be more common in men and adults &ge;65 years old), confusion, delusions, depression, dizziness, drowsiness, dyschromia, dystonia, falling, fatigue, hallucination, headache, illusion, insomnia, irritability, nervousness, paranoia, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, decreased appetite, diarrhea, nausea (may be more common in women), vomiting, xerostomia (may be more common in women)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Benign prostatic hypertrophy, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Joint swelling, muscle spasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, cataract (may be more common in women), xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dry nose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening): Abnormal gait, abnormality in thinking, acute respiratory tract failure, aggressive behavior, agranulocytosis, amnesia, anaphylaxis, cardiac arrhythmia (including malignant arrhythmias), cardiac failure, coma, corneal edema, decreased libido, decreased visual acuity, delirium, diaphoresis, dysphagia, dyspnea, eczema, edema, EEG pattern changes, euphoria, fever, hyperkinesia, hypersensitivity reaction, hypertension, hypertonia, hypokinesia, hypotension, impulse control disorder, increased blood urea nitrogen, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased libido, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, keratitis, leukocytosis, leukopenia, mania, mydriasis, neuroleptic malignant syndrome (associated with dosage reduction or abrupt withdrawal of amantadine), neutropenia, oculogyric crisis, optic nerve palsy, paresthesia, pathological gambling, pruritus, psychosis, pulmonary edema, seizure, skin photosensitivity, skin rash, slurred speech, stupor, tachycardia, tachypnea, tremor, urinary retention, visual disturbance (including punctate subepithelial or other corneal opacity), weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132656\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amantadine or any component of the formulation; end-stage renal disease (CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>) (extended release only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132639\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Patients taking amantadine for Parkinson disease have reported falling asleep while engaged in activities of daily living, sometimes without warning. Patients with a concomitant sleep disorder may be at a greater risk. There is insufficient information that dose reduction will eliminate episodes of falling asleep or daytime somnolence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Dopamine agonists used for Parkinson disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), urges to spend money, and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions, and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: Has been associated with neuroleptic malignant syndrome (associated with dose reduction or abrupt discontinuation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Visual and auditory hallucinations, delusions, illusions, and paranoia were reported in clinical trials; monitor for the occurrence of these symptoms especially at initiation and after dose increases. Use with caution in patients with uncontrolled psychosis or severe psychoneurosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal ideation/depression: There have been reports of suicidal ideation/attempt and depression in patients with and without a history of psychiatric illness. May exacerbate mental problems in patients with a history of mental illness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure, peripheral edema, or orthostatic hypotension; dizziness, syncope, orthostatic hypotension, presyncope, postural dizziness, and hypotension have been reported in clinical trials. Dosage reduction may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eczema: Use with caution in patients with a history of recurrent and eczematoid dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Avoid in untreated angle closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; rarely, reversible elevations in transaminases have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Influenza A: Appropriate use: Consult current guidelines. Due to increased resistance, the ACIP has recommended that rimantadine and amantadine no longer be used for the treatment or prophylaxis of influenza A in the United States until susceptibility has been re-established (CDC 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended. Use of the extended-release capsule is contraindicated in end-stage renal disease (CrCl &lt;15 mL/minute/1.73 m<sup>2</sup>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to CNS effects (using 2 divided daily doses of immediate-release products may minimize this effect). These patients may require dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Tolerance has also been reported with long-term use (Zubenko1984).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal syndrome: May cause agitation, anxiety, delirium, delusions, depression, hallucinations, paranoia, parkinsonian crisis, slurred speech, or stupor. Upon discontinuation of amantadine therapy, gradually taper dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298728\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132644\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13387&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Amantadine. Alcohol may also cause dose-dumping for at least one extended-release amantadine product.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Amantadine may enhance the anticholinergic effect of Anticholinergic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (First Generation [Typical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): Amantadine may enhance the anticholinergic effect of Glycopyrrolate (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propiverine: May enhance the adverse/toxic effect of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Amantadine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132646\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132660\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies and teratogenic events have been observed in humans (case reports) (Seier 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treatment for Parkinson disease is needed, agents other than amantadine are recommended in pregnant women (Seier 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Other agents are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Appropriate antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (CDC 2011; CDC 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044969\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function; mental status, monitor for signs of neurotoxicity; periodic skin exam for melanoma, blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132638\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiviral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The mechanism of amantadine&rsquo;s antiviral activity has not been fully elucidated. It appears to primarily prevent the release of infectious viral nucleic acid into the host cell by interfering with the transmembrane domain of the viral M2 protein. Amantadine is also known to prevent viral assembly during replication. Amantadine inhibits the replication of influenza A virus isolates from each of the subtypes (ie, H1N1, H2N2 and H3N2), but has very little or no activity against influenza B virus isolates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parkinson disease:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The exact mechanism of amantadine in the treatment of Parkinson disease and drug-induced extrapyramidal symptoms is not known. Data from early animal studies suggest that amantadine may have direct and indirect effects on dopamine neurons; however, recent studies have demonstrated that amantadine is a weak, noncompetitive NMDA receptor antagonist. Although amantadine has not been shown to possess direct anticholinergic activity, clinically, it exhibits anticholinergic-like side effects (dry mouth, urinary retention, and constipation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132655\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Antidyskinetic: Within 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Normal: 3 to 8 L/kg; Renal failure: 5.1 &plusmn; 0.2 L/kg (Aoki 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Normal renal function: ~67%; Hemodialysis: ~59% (Aoki 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not appreciable; small amounts of an acetyl metabolite identified</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release: 86% to 94% (Aoki 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Normal renal function: 16 &plusmn; 6 hours (9 to 31 hours); Healthy, older (&ge;60 years) males: 29 hours (range: 20 to 41 hours) (Aoki 1988); End-stage renal disease: 8 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Extended release: 12 hours (mean; range: 6 to 20 hours); immediate release: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 90% unchanged) by glomerular filtration and tubular secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132659\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Gocovri Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">68.5 mg (60): $2,850.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mg (60): $2,850.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Amantadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $201.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Amantadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (473 mL): $72.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amantadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $228.33</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132661\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actison (AR, PE);</li>\n      <li>Amadin (BD);</li>\n      <li>Amanda (TW);</li>\n      <li>Amandin (HK, TW);</li>\n      <li>Amandine (UY);</li>\n      <li>Amanta (KR);</li>\n      <li>Amantadin (EE);</li>\n      <li>Amantan (LU);</li>\n      <li>Amantin (BD);</li>\n      <li>Amantix (CO, PL);</li>\n      <li>Amantrel (IN);</li>\n      <li>Amantril (BD);</li>\n      <li>Amantyn (UA);</li>\n      <li>Ampakine (AR, PE);</li>\n      <li>Atadin (TW);</li>\n      <li>Atarin (CL);</li>\n      <li>Atenergine (JP);</li>\n      <li>Enzil (HK, TW);</li>\n      <li>Hofcomant (AT, FI);</li>\n      <li>Influ (BD, TW);</li>\n      <li>Influ-A (IL);</li>\n      <li>Kinestrel (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Lysovir (GB);</li>\n      <li>Mantadan (IT);</li>\n      <li>Mantadix (FR, LU);</li>\n      <li>Mantidan (BR);</li>\n      <li>Mantra (CL);</li>\n      <li>Midantan (RU);</li>\n      <li>Neomidantan (LV, RO, RU);</li>\n      <li>Neomidantin (UA);</li>\n      <li>Parkadina (PT);</li>\n      <li>Parkintrel (KR);</li>\n      <li>PK Merz (CU);</li>\n      <li>PK-Merz (AT, BF, BG, BH, BJ, CH, CI, CL, CR, CY, CZ, DE, DO, EE, ET, GH, GM, GN, GT, HK, HN, HR, HU, IL, IQ, IR, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, OM, PA, PH, PK, PY, QA, RU, SA, SC, SD, SK, SL, SN, SV, SY, TN, TR, TW, TZ, UA, UG, YE, ZM, ZW);</li>\n      <li>Prayanol (CL);</li>\n      <li>Symadin (ZA);</li>\n      <li>Symmetrel (AE, AU, BH, CH, CY, EG, GR, HK, HR, IE, IQ, IR, JP, LB, LY, MT, NL, NO, NZ, OM, SG, SY, YE, ZA);</li>\n      <li>Tregor (DE);</li>\n      <li>Viergyt-K (RO);</li>\n      <li>Viregyt (HU);</li>\n      <li>Viregyt K (PL);</li>\n      <li>Viregyt-K (BG, CZ);</li>\n      <li>Virofral (DK);</li>\n      <li>Virosol (AR, PE);</li>\n      <li>Zintergia (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aoki FY and Sitar DS, &ldquo;Clinical Pharmacokinetics of Amantadine Hydrochloride,&rdquo; <i>Clin Pharmacokinet</i>, 1988, 14(1):35-51. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/3280212/pubmed\" target=\"_blank\" id=\"3280212\">3280212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beers SR, Skold A, Dixon CE, et al, &quot;Neurobehavioral Effects of Amantadine After Pediatric Traumatic Brain Injury: A Preliminary Report,&quot; <i>J Head Trauma Rehabil</i>, 2005, 20(5):450-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/16170253/pubmed\" target=\"_blank\" id=\"16170253\">16170253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot;  <i>MMWR Surveill Summ</i>, 2011, 60(1):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/21248682/pubmed\" target=\"_blank\" id=\"21248682\">21248682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Interim Guidance: Considerations Regarding 2009 Novel H1N1 Flu Virus in Intrapartum and Postpartum Hospital Settings,&quot;  Available at <a href=\"http://www.cdc.gov/h1n1flu/guidance/obstetric.htm\" target=\"_blank\">http://www.cdc.gov/h1n1flu/guidance/obstetric.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/12755288/pubmed\" target=\"_blank\" id=\"12755288\">12755288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; MMWR Recomm Rep, 2008, 56 (early release):1-60. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e717a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e717a1.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chitnis T, Krupp L, Yeh A, et al, &quot;Pediatric Multiple Sclerosis,&quot; <i>Neurol Clin</i>, 2011, 29(2):481-505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/21439455/pubmed\" target=\"_blank\" id=\"21439455\">21439455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donfrancesco R, Calderoni D, and Vitiello B, &quot;Open-Label Amantadine in Children With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2007, 17(5):657-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/17979585/pubmed\" target=\"_blank\" id=\"17979585\">17979585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giacino JT, Whyte J, Bagiella E, et al, &quot;Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury,&quot; <i>N Engl J Med</i>, 2012, 366(9):819-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/22375973/pubmed\" target=\"_blank\" id=\"22375973\">22375973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green LB, Hornyak JE, and Hurvitz EA, &quot;Amantadine in Pediatric Patients With Traumatic Brain Injury: A Retrospective, Case-Controlled Study,&quot; <i>Am J Phys Med Rehabil</i>, 2004, 83(12):893-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/15624567/pubmed\" target=\"_blank\" id=\"15624567\">15624567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King BH, Wright DM, Handen BL, et al, &quot;Double-Blind, Placebo-Controlled Study of Amantadine Hydrochloride in the Treatment of Children With Autistic Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2001a, 40(6):658-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/11392343/pubmed\" target=\"_blank\" id=\"11392343\">11392343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King BH, Wright DM, Snape M, et al, &quot;Case Series: Amantadine Open-Label Treatment of Impulsive and Aggressive Behavior in Hospitalized Children With Developmental Disabilities,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2001, 40(6):654-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/11392342/pubmed\" target=\"_blank\" id=\"11392342\">11392342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahon MA, Vargus-Adams JN, Michaud LJ, et al, &quot;Effects of Amantadine in Children With Impaired Consciousness Caused by Acquired Brain Injury: A Pilot Study,&quot; <i>Am J Phys Med Rehabil</i>, 2009, 88(7):525-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/19404190/pubmed\" target=\"_blank\" id=\"19404190\">19404190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohammadi MR, Kazemi MR, Zia E, et al, &quot;Amantadine Versus Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Trial,&quot; <i>Hum Psychopharmacol</i>, 2010, 25(7-8):560-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/21312290/pubmed\" target=\"_blank\" id=\"21312290\">21312290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patrick PD, Blackman JA, Mabry JL, et al, &quot;Dopamine Agonist Therapy in Low-Response Children Following Traumatic Brain Injury,&quot; <i>J Child Neurol</i>, 2006, 21(10):879-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/17005105/pubmed\" target=\"_blank\" id=\"17005105\">17005105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pohl D, Waubant E, Banwell B, et al, &quot;Treatment of Pediatric Multiple Sclerosis and Variants,&quot; <i>Neurology</i>, 2007, 68(16 Suppl 2):54-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/17438239/pubmed\" target=\"_blank\" id=\"17438239\">17438239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strong DK, Eisenstat DD, Bryson SM, et al, &ldquo;Amantadine Neurotoxicity in a Pediatric Patient With Renal Insufficiency,&rdquo; <i>DICP</i>, 1991, 25(11):1175-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/1763530/pubmed\" target=\"_blank\" id=\"1763530\">1763530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson AJ, Toosy AT, and Ciccarelli O, &quot;Pharmacological Management of Symptoms in Multiple Sclerosis: Current Approaches and Future Directions,&quot; <i>Lancet Neurol</i>, 2010, 9(12):1182-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/21087742/pubmed\" target=\"_blank\" id=\"21087742\">21087742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vargus-Adams JN, McMahon MA, Michaud LJ, et al, &quot;Pharmacokinetics of Amantadine in Children With Impaired Consciousness Due to Acquired Brain Injury: Preliminary Findings Using a Sparse-Sampling Technique,&quot; <i>PMR</i>, 2010, 2(1):37-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/20129511/pubmed\" target=\"_blank\" id=\"20129511\">20129511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams SE, &quot;Amantadine Treatment Following Traumatic Brain Injury in Children,&quot; <i>Brain Inj</i>, 2007, 21(9):885-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/17729042/pubmed\" target=\"_blank\" id=\"17729042\">17729042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amantadine-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13387 Version 183.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50907068\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50642731\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1044970\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1044963\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132650\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F132635\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F51128489\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15574778\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F132671\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1044972\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132723\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132720\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132656\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132639\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298728\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132644\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132646\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F132660\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1044969\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132638\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F132655\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F132659\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132661\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13387|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">Amantadine: Drug information</a></li><li><a href=\"topic.htm?path=amantadine-patient-drug-information\" class=\"drug drug_patient\">Amantadine: Patient drug information</a></li></ul></div></div>","javascript":null}